CO6382154A2 - Sales de fingolimod - Google Patents
Sales de fingolimodInfo
- Publication number
- CO6382154A2 CO6382154A2 CO11058592A CO11058592A CO6382154A2 CO 6382154 A2 CO6382154 A2 CO 6382154A2 CO 11058592 A CO11058592 A CO 11058592A CO 11058592 A CO11058592 A CO 11058592A CO 6382154 A2 CO6382154 A2 CO 6382154A2
- Authority
- CO
- Colombia
- Prior art keywords
- salts
- fingolimod
- fingolimod salts
- immunosuppressants
- polymorphs
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
- C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/08—Acetic acid
- C07C53/10—Salts thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
- C07C53/122—Propionic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C63/00—Compounds having carboxyl groups bound to a carbon atoms of six-membered aromatic rings
- C07C63/04—Monocyclic monocarboxylic acids
- C07C63/06—Benzoic acid
- C07C63/08—Salts thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Pyridine Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente invención se refiere a sales, polimorfos, e hidratos de 2-amino-2-[2-(4-alquilo C2-20-fenilo)-etil]-propan-1,3-diol, y al uso de los mismos, en particular en el tratamiento o la prevención de diferentes condiciones autoinmunes, ya que se ha encontrado que los compuestos son útiles como inmunosupresores
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08168862 | 2008-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6382154A2 true CO6382154A2 (es) | 2012-02-15 |
Family
ID=42062355
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11058592A CO6382154A2 (es) | 2008-11-11 | 2011-05-12 | Sales de fingolimod |
Country Status (20)
Country | Link |
---|---|
US (2) | US8680146B2 (es) |
EP (1) | EP2358660A2 (es) |
JP (2) | JP2012508215A (es) |
KR (1) | KR20110086142A (es) |
CN (2) | CN105198760A (es) |
AU (1) | AU2009315735B2 (es) |
BR (1) | BRPI0921533A2 (es) |
CA (1) | CA2741974A1 (es) |
CL (1) | CL2011001041A1 (es) |
CO (1) | CO6382154A2 (es) |
EC (1) | ECSP11011121A (es) |
IL (1) | IL212073A0 (es) |
MA (1) | MA32877B1 (es) |
MX (1) | MX2011004924A (es) |
NZ (1) | NZ591999A (es) |
PE (1) | PE20120012A1 (es) |
RU (1) | RU2543621C2 (es) |
TN (1) | TN2011000187A1 (es) |
WO (1) | WO2010055027A2 (es) |
ZA (1) | ZA201102272B (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5042215B2 (ja) | 2005-05-26 | 2012-10-03 | ニューロン システムズ, インコーポレイテッド | 網膜疾患を処置するための組成物および方法 |
BRPI0921533A2 (pt) * | 2008-11-11 | 2016-01-12 | Novartis Ag | composto orgânicos |
EP2456752A2 (en) | 2009-07-24 | 2012-05-30 | ratiopharm GmbH | Process for producing fingolimod salts |
JP2014503478A (ja) | 2010-10-28 | 2014-02-13 | マピ ファーマ リミテッド | フィンゴリモドの調製のための中間の化合物およびプロセス |
WO2012071524A1 (en) | 2010-11-24 | 2012-05-31 | Ratiopharm Gmbh | Arylsulfonate salts of fingolimod and processes for preparation thereof |
EP2505589A1 (en) | 2011-04-01 | 2012-10-03 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Novel sphingolipid heterocyclic compounds as modulators of sphingolipid signaling and uses thereof |
JO3177B1 (ar) | 2011-04-01 | 2018-03-08 | Novartis Ag | تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول |
CN102887829B (zh) * | 2012-09-05 | 2014-07-02 | 中国科学院上海药物研究所 | 芬戈莫德粘酸盐及其晶体的制备方法和用途 |
JP6484567B2 (ja) | 2013-03-05 | 2019-03-13 | バイオコン・リミテッドBiocon Limited | 2−アミノ−1,3−プロパンジオール化合物およびその塩の製造のための方法 |
WO2015053879A1 (en) | 2013-10-11 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Sphingosine-1-phosphate receptor agonist iontophoretic devices and methods of using the same |
KR101820330B1 (ko) | 2013-10-11 | 2018-01-19 | 테이코쿠 팔마 유에스에이, 인코포레이티드 | 국소 스핑고신-1-포스페이트 수용체 효현제 제형 및 이의 사용 방법 |
US9925138B2 (en) | 2015-01-20 | 2018-03-27 | Handa Pharmaceuticals, Llc | Stable solid fingolimod dosage forms |
AU2017264697A1 (en) | 2016-05-09 | 2018-11-22 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
CN109563057B (zh) | 2016-05-31 | 2022-06-24 | 大鹏药品工业株式会社 | 磺酰胺化合物或其盐 |
RU2627691C1 (ru) * | 2016-07-06 | 2017-08-10 | Олег Ростиславович Михайлов | Кристаллическая η-модификация 2-амино-2-(2-(4-октилфенил)этил)пропан-1,3-диол гидрохлорида, способ её получения и фармацевтическая композиция на её основе |
EP3694500A4 (en) | 2017-10-10 | 2021-06-30 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
WO2020006329A1 (en) * | 2018-06-29 | 2020-01-02 | Forma Therapeutics, Inc. | Salts of (s)-(5-cyclobutoxy-2-methyl-6-(1-(piperidin-4-yl)-1h-pyrazol-4-yl)-3,4-dihydroquinolin-1(2h)-yl)(cyclopropyl)methanone and solid forms thereof |
JP2021533154A (ja) * | 2018-08-06 | 2021-12-02 | アルデイラ セラピューティクス, インコーポレイテッド | 多形化合物およびその使用 |
CA3156298A1 (en) | 2019-10-31 | 2021-05-06 | Laetitia POUZOL | Combination of a cxcr7 antagonist with an s1p1 receptor modulator |
EP4353709A1 (en) * | 2021-05-31 | 2024-04-17 | Shanghai Yonsun Biotechnology Co., Ltd. | Pharmaceutical salt of fingolimod, preparation method therefor, pharmaceutical composition containing same and use thereof |
EP4212156A1 (en) | 2022-01-13 | 2023-07-19 | Abivax | Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0155015B1 (ko) | 1992-10-21 | 1998-12-01 | 고우야 마사시 | 2-아미노-1,3-프로판디올 화합물 및 면역 억제제 |
ECSP951461A (es) | 1995-06-07 | 1998-04-07 | SINTESIS DE 3- {4-(2- AMINOETOXI) BENZOIL]-2-ARIL-6- HIDROXIBENZO {b] TIOFENOS (CASO X- 9295B) | |
ECSP972265A (es) | 1997-09-23 | 1998-11-30 | Dihidrato de d-olanzapina | |
FR2785607B1 (fr) | 1998-11-09 | 2001-02-09 | Rhodia Chimie Sa | Procede de preparation de tris(ether-amine) |
PT1457478T (pt) * | 1998-11-11 | 2017-10-26 | Mitsubishi Pharma Corp | Produção de 2-amino-2-[2-(4-alquil-fenil)etil]propano-1,3-dióis |
JP4627356B2 (ja) * | 1999-06-30 | 2011-02-09 | 松森 昭 | ウイルス性心筋炎の予防または治療薬剤 |
CN1524002A (zh) * | 2001-06-08 | 2004-08-25 | ��˹��ŵ�� | 治疗或预防产胰岛素细胞的移植排斥反应 |
KR20120125398A (ko) * | 2002-05-16 | 2012-11-14 | 노파르티스 아게 | 암에서 edg 수용체 결합제의 용도 |
GB0217152D0 (en) * | 2002-07-24 | 2002-09-04 | Novartis Ag | Organic compounds |
HUE028247T2 (en) | 2003-04-08 | 2016-12-28 | Novartis Ag | A solid oral composition comprising S1P receptor agonist and sugar alcohol |
JP5021488B2 (ja) * | 2004-12-21 | 2012-09-05 | メルク セローノ ソシエテ アノニム | スルホニルアミノ環式誘導体及びその使用 |
GT200600350A (es) | 2005-08-09 | 2007-03-28 | Formulaciones líquidas | |
US20080221200A1 (en) * | 2005-09-30 | 2008-09-11 | Malcolm Allison | Combination of Organic Compounds |
ES2414205T3 (es) * | 2006-06-02 | 2013-07-18 | The Ohio State University Research Foundation | Agentes terapéuticos para el tratamiento de linfoma de células del manto |
US7985586B2 (en) * | 2008-02-04 | 2011-07-26 | Georgia Health Sciences University | Oligodendrocyte precursor cell composition and methods of use |
BRPI0921533A2 (pt) * | 2008-11-11 | 2016-01-12 | Novartis Ag | composto orgânicos |
-
2009
- 2009-11-10 BR BRPI0921533A patent/BRPI0921533A2/pt not_active IP Right Cessation
- 2009-11-10 CA CA2741974A patent/CA2741974A1/en not_active Abandoned
- 2009-11-10 US US13/128,832 patent/US8680146B2/en not_active Expired - Fee Related
- 2009-11-10 PE PE2011000987A patent/PE20120012A1/es not_active Application Discontinuation
- 2009-11-10 JP JP2011535129A patent/JP2012508215A/ja not_active Withdrawn
- 2009-11-10 EP EP09752168A patent/EP2358660A2/en not_active Withdrawn
- 2009-11-10 WO PCT/EP2009/064889 patent/WO2010055027A2/en active Application Filing
- 2009-11-10 CN CN201510547567.5A patent/CN105198760A/zh active Pending
- 2009-11-10 NZ NZ591999A patent/NZ591999A/xx not_active IP Right Cessation
- 2009-11-10 AU AU2009315735A patent/AU2009315735B2/en not_active Ceased
- 2009-11-10 MX MX2011004924A patent/MX2011004924A/es active IP Right Grant
- 2009-11-10 RU RU2011123365/04A patent/RU2543621C2/ru not_active IP Right Cessation
- 2009-11-10 CN CN2009801448205A patent/CN102256933A/zh active Pending
- 2009-11-10 KR KR1020117013304A patent/KR20110086142A/ko not_active Application Discontinuation
-
2011
- 2011-03-28 ZA ZA2011/02272A patent/ZA201102272B/en unknown
- 2011-03-31 IL IL212073A patent/IL212073A0/en unknown
- 2011-04-19 TN TN2011000187A patent/TN2011000187A1/fr unknown
- 2011-05-10 CL CL2011001041A patent/CL2011001041A1/es unknown
- 2011-05-12 CO CO11058592A patent/CO6382154A2/es not_active Application Discontinuation
- 2011-06-03 MA MA33910A patent/MA32877B1/fr unknown
- 2011-06-10 EC EC2011011121A patent/ECSP11011121A/es unknown
-
2014
- 2014-02-13 US US14/179,807 patent/US20140235722A1/en not_active Abandoned
-
2015
- 2015-04-24 JP JP2015089480A patent/JP2015178503A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
ECSP11011121A (es) | 2011-07-29 |
US8680146B2 (en) | 2014-03-25 |
US20110218248A1 (en) | 2011-09-08 |
EP2358660A2 (en) | 2011-08-24 |
BRPI0921533A2 (pt) | 2016-01-12 |
AU2009315735B2 (en) | 2013-01-10 |
TN2011000187A1 (en) | 2012-12-17 |
RU2011123365A (ru) | 2012-12-20 |
MA32877B1 (fr) | 2011-12-01 |
KR20110086142A (ko) | 2011-07-27 |
PE20120012A1 (es) | 2012-02-02 |
JP2012508215A (ja) | 2012-04-05 |
MX2011004924A (es) | 2011-05-30 |
AU2009315735A1 (en) | 2010-05-20 |
ZA201102272B (en) | 2011-12-28 |
US20140235722A1 (en) | 2014-08-21 |
WO2010055027A3 (en) | 2010-08-19 |
NZ591999A (en) | 2013-06-28 |
JP2015178503A (ja) | 2015-10-08 |
CA2741974A1 (en) | 2010-05-20 |
WO2010055027A2 (en) | 2010-05-20 |
CN105198760A (zh) | 2015-12-30 |
CL2011001041A1 (es) | 2011-10-07 |
RU2543621C2 (ru) | 2015-03-10 |
IL212073A0 (en) | 2011-06-30 |
CN102256933A (zh) | 2011-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6382154A2 (es) | Sales de fingolimod | |
CL2014003191A1 (es) | Compuestos que inhiben la actividad de catecol o -metiltransferasa; su uso contra el parkinson. | |
HK1254470A1 (zh) | 3'平伏氟取代的神經氨酸酶抑制劑化合物、組合物及其用作抗病毒劑的方法 | |
AR071812A1 (es) | Composicion tonalizadora | |
SMT201400179B (it) | 1,2,5-Ossadiazoli come inibitori di indoleamina 2,3-diossigenasi | |
CU20110052A7 (es) | Compuestos orgánicos | |
CO6781474A2 (es) | N-bencil carboxamidas heterocíclicas | |
ECSP14013329A (es) | Compuestos de arylcarbonil-4-oxy-piperidina utilizados para el tratamiento de enfermedades neurodegenerativas | |
BR112014003412A2 (pt) | compostos de fórmula i, processo, compostos de fórmula xii, viii e xi, composições agroquímicas, utilização e semente revestida | |
BRPI1012638B8 (pt) | métodos e intermediários para preparar agentes farmacêuticos | |
BR112014002922A2 (pt) | compostos da fórmula i, processo de preparação de compostos da fórmula i, compostos da formula xii, viii e xi, composições agroquímicas, uso e semente | |
BR112013033534A2 (pt) | métodos e composições para inibição de reabsorção de osso | |
NI201100223A (es) | Derivados de imidazolidina 2 -0ne 1,3 - disustituidos como inhibidores de cyp 17 | |
AR077047A1 (es) | Polimeros colorantes cationicos | |
BRPI0914069A2 (pt) | composição de vacina para uso contra o influenza | |
UY33549A (es) | Quinolil aminas como agentes inhibidores de las quinasas | |
UY33655A (es) | Co-cristales y sales de inhibidores de ccr30 | |
CR20130081A (es) | Composición para el tratamiento de plantas y métodos para su uso | |
ECSP14004595A (es) | 2-tiopirimidinonas | |
DOP2015000060A (es) | Profármacos de aminoquinazolina inhibidora de cinasa | |
UY31738A (es) | Inhibidores a base de hidroxamato de desacetilasas b | |
CO6821965A2 (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
BRPI1010571A2 (pt) | processo para a preparação de um composto útil como um inibidor de tafla. | |
BRPI0919635A2 (pt) | processo para preparação de cinacalcet | |
CR20120592A (es) | Intermedios de agomelatina y métodos de preparación de estos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |